Efficacy and safety of single-dose artesunate plus sulfalene/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial

• Published in: Parasites & vectors 2024-06, Vol.17 (1), p.279-12, Article 279
• Main Authors: Obonyo, Charles O, Rawago, Fredrick O, Makworo, Nicholas K, Muok, Erick M O
• Format: Article
• Language: English
• Subjects: Adolescent; Animals; Anthelmintics - administration & dosage; Anthelmintics - adverse effects; Anthelmintics - therapeutic use; Artemisinin-based combinations; Artemisinins - administration & dosage; Artemisinins - adverse effects; Artemisinins - therapeutic use; Artesunate - administration & dosage; Artesunate - therapeutic use; Artesunate plus sulfalene-pyrimethamine; Child; Dosage and administration; Drug Combinations; Drug resistance; Drug therapy; Drug Therapy, Combination; Female; Humans; Kenya; Male; Parasite Egg Count; Patient outcomes; Praziquantel; Praziquantel - administration & dosage; Praziquantel - adverse effects; Praziquantel - therapeutic use; Prevention; Pyrimethamine - administration & dosage; Pyrimethamine - adverse effects; Pyrimethamine - therapeutic use; Schistosoma haematobium; Schistosoma haematobium - drug effects; Schistosoma mansoni; Schistosoma mansoni - drug effects; Schistosomiasis; Schistosomiasis haematobia - drug therapy; Schistosomiasis mansoni - drug therapy; Sulfalene - administration & dosage; Sulfalene - adverse effects; Sulfalene - therapeutic use; Treatment Outcome
• ISSN: 1756-3305; 1756-3305
• DOI: 10.1186/s13071-024-06359-6

Reliance on praziquantel for the treatment and control of schistosomiasis is likely to facilitate the emergence of drug resistance. Combination therapy targeting adult and juvenile schistosome worms is urgently needed to improve praziquantel efficacy and delay the potential development of drug resistance. We assessed the efficacy and safety of single-dose praziquantel combined with single-dose artesunate plus sulfalene-pyrimethamine in the treatment of Kenyan children with schistosomiasis. This was an open-label, randomised clinical trial involving 426 school-aged children (7-15 years old) diagnosed with Schistosoma mansoni (by Kato-Katz) or S. haematobium (by urine filtration). They were randomly assigned (1:1:1) to receive a single dose of praziquantel (40 mg/kg), a single dose of artesunate plus sulfalene-pyrimethamine (12 mg/kg artesunate) or combination therapy using a single dose of praziquantel (40 mg/kg) combined with a single dose of artesunate plus sulfalene-pyrimethamine (12 mg/kg artesunate). The primary outcome was cure and egg reduction rates at 6 weeks post-treatment in the available case population. Adverse events were assessed within 3 h after treatment. Of the 426 children enrolled, 135 received praziquantel, 150 received artesunate plus sulfalene-pyrimethamine, and 141 received combination therapy. Outcome data were available for 348 (81.7%) children. For S. mansoni-infected children (n = 335), the cure rates were 75.6%, 60.7%, and 77.8%, and the egg reduction rates were 80.1%, 85.0%, and 88.4% for praziquantel, artesunate plus sulfalene-pyrimethamine, and combination therapy, respectively. For S. haematobium-infected children (n = 145), the corresponding cure rates were 81.4%, 71.1%, and 82.2%, and the egg reduction rates were 95.6%, 97.1%, and 97.7%, respectively. Seventy-one (16.7%) children reported mild-intensity adverse events. The drugs were well tolerated and no serious adverse events were reported. A single oral dose of praziquantel combined with artesunate plus sulfalene-pyrimethamine cured a high proportion of children with S. haematobium but did not significantly improve the treatment efficacy for either urinary or intestinal schistosomiasis. Sequential administration of praziquantel and artesunate plus sulfalene-pyrimethamine may enhance the efficacy and safety outcomes.